The treatment landscape for metastatic HR+/HER2- and triple-negative breast cancer (TNBC) is rapidly evolving with the emergence of novel infusion-based therapies, including antibody-drug conjugates and targeted therapies. Tune in to this recording from the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference 2024 to learn about cutting-edge strategies that will enable pharmacists to optimize use of these novel therapies. Learn from experts as they discuss current challenges, emerging trial data, adverse event mitigation, dose modifications, and strategies to support coordinated, equitable, evidence-based, and guideline-aligned treatment and management of breast cancer. Combine this knowledge with a concise point-of-care resource to equip you with evidence-based best practices and recommendations for administering infusion therapies and managing adverse events in patients with HR+/HER2- and triple-negative breast cancer.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/optimizing-treatment-infusion-based-therapies-hr-her2-breast-cancer-tnbc
- Start Date: 2024-05-29 05:00:00
- End Date: 2024-05-29 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Gilead Sciences, Inc. - Amount: 87500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all